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Abstract
The dynamics of tumor burden, secreted proteins or other biomarkers over time, is often
used to evaluate the effectiveness of therapy and to predict outcomes for patients. Many
methods have been proposed to investigate longitudinal trends to better characterize
patients and to understand disease progression. However, most approaches assume a
homogeneous patient population and a uniform response trajectory over time and across
patients. Here, we present a mixture piecewise linear Bayesian hierarchical model, which
takes into account both population heterogeneity and nonlinear relationships between bio-
markers and time. Simulation results show that our method was able to classify subjects
according to their patterns of treatment response with greater than 80% accuracy in the
three scenarios tested. We then applied our model to a large randomized controlled phase
III clinical trial of multiple myeloma patients. Analysis results suggest that the longitudinal
tumor burden trajectories in multiple myeloma patients are heterogeneous and nonlinear,
even among patients assigned to the same treatment cohort. In addition, between cohorts,
there are distinct differences in terms of the regression parameters and the distributions
among categories in the mixture. Those results imply that longitudinal data from clinical trials
may harbor unobserved subgroups and nonlinear relationships; accounting for both may be
important for analyzing longitudinal data.
Introduction
Mixed-effects models are particularly useful in medical research because of their ability to han-
dle imbalances in the number of observations across patients and to identify between-subject
and within-subject sources of variability [1–3]. Progress to extend mixed-effects models to
include heterogeneity in data has been made by incorporating a finite mixture into the model
[4, 5]. This extension is particularly relevant to clinical research, since clinical data often con-
tain unobserved categorical variables corresponding to, for example, “responders” or “non-
responders” to a given treatment. Ignoring such mixtures may result in biases in estimates. Xu
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and Hedeker investigated this idea and found there is ample evidence of non-homogeneous
responses in two large psychiatric clinical trials [6]. Ketchum et al. further extended the
mixed-effects mixture models to allow for differences in the variance-covariance matrices [7].
These improvements enable the random-effects models to better characterize heterogeneity in
data. A book chapter by Verbeke and Molenberghs provides an excellent summary of hetero-
geneous mixed models [8].
In addition to population heterogeneity, changes in functional relationships between
response variables and explanatory variables, particularly with time, are ubiquitous in longitu-
dinal studies: HIV-1 viral load [9, 10], hepatitis B/C viral load [11, 12] and BCR-ABL expres-
sion levels in chronic myeloid leukemia [13, 14]. In those examples, biomarkers exhibit
nonlinear changes over time, many of which are bi-phasic in nature—that is, patients bio-
markers have two distinct patterns over time rather than one uniform trajectory. An example
of bi-phasic decline patterns is that in some chronic myeloid leukemia patients, the initial
decline of BCR-ABL expression levels is much faster than later declines, whereas in other
patients the decline is uniform over time [13, 14]. These observations are contrary to the
assumptions of many models that parameters are invariant over time. One method for
accounting for changes in the longitudinal relationships over time is provided by nonlinear
mixed-effects models [15, 16]. Morrel et al. applied a piecewise nonlinear mixed-effects model
to a prostate cancer data set and found that patients with local lesions and metastatic lesions
have similar initial prostate-specific antigen (PSA) trajectories. However, they found that the
rates of PSA increase in a later phase were larger in patients with metastatic lesions than
patients with local lesions. Naumova et al. used a piecewise mixed-effect model to analyze a
prospective study on the development of obesity in female adolescents [17]. Cudeck and
Klebe, and Harring et al. applied similar ideas to psychology-related data sets [18, 19]. Those
examples demonstrate the flexibility of nonlinear mixed-effects models in investigating chang-
ing functional relationships over time.
Both heterogeneity in patient populations and changes in the longitudinal relationship have
been addressed separately in several publications [6, 7, 15–19]; however, only a few publica-
tions have tackled both problems simultaneously. Pauler and Laird introduced a general
framework for finite mixtures of nonlinear hierarchical models; they applied their methods to
investigate non-compliance in a HIV clinical trial [20]. In their application, the mixture con-
sists of a constant mean model for the compliant patients and a piecewise linear model for the
non-compliant patients. Recently, Lu and Huang extended the general framework proposed
by Pauler and Laird [20] to incorporate skewness in the distributions of individual regression
parameters, relaxing the normal assumption [21]; they applied their methods to analyze a HIV
viral load data set [22]. Their underlying nonlinear mixed-effects model was formulated based
on the model structure of an ordinary differential equation (ODE) model describing viral
loads over time [23]. One caveat associated with those approaches is that their models require
extensive prior biological knowledge in order to specify the nonlinear models before analyzing
the data. Misspecification of the model may have detrimental effects on parameter estimation
and patient classification. Particularly, if the differences between categories in the mixture are
not well separated, specifying the model becomes an even more challenging problem.
To address this issue, we developed a piecewise linear random-effects mixture model that
does not require any prior knowledge on the model structure to account for both heterogene-
ity and change in the longitudinal relationship over time. The only assumptions of this model
are that the underlying data may contain a mixture of mono- and bi-phasic observations, and
that the bi-phasic observations are piecewise linear; no further constraints on the intercepts
and slopes are necessary. The primary purpose of this model is to detect unobserved subgroups
in a patient population and nonlinear longitudinal relationships over time. This method is
Mixture piecewise linear Bayesian hierarchical model
PLOS ONE | https://doi.org/10.1371/journal.pone.0180756 July 19, 2017 2 / 19
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
particularly useful for current clinical trials, which often include diagnostic and prognostic
hypotheses. With periodical follow-up visits gathering biomarker data, parameters associated
with heterogeneous changes in biomarker trends can be detected with this method. Given the
usually limited number of follow-up measurements in clinical trials, the current implementa-
tion of this model focuses primarily on mono- vs. bi-phasic changes; however, our model can
easily be generalized to include multi-phasic changes and multi-category mixtures. In addi-
tion, because of the piecewise linear nature of the proposed model, other clinically relevant
covariates can also easily be included.
Materials and methods
We designed a mixture piecewise linear Bayesian hierarchical model to estimate regression
parameters and to determine the posterior distributions of these parameters, while accounting
for both population heterogeneity and changes in longitudinal relationships over time. We
consider situations in which the patient population consists two latent subpopulations: mono-
phasic and bi-phasic patients. The individual-level trajectories for mono-phasic and bi-phasic
patients are shown in Eq (1). Throughout the text, we use subscripts S and B to denote mono-
(i.e. single-) and bi-phasic patients, respectively. For the ith patient with a total of Mi observa-
tions, the dependent variable yij, corresponding to the quantitative measure of disease burden,
which may either follow a mono-phasic or a bi-phasic regression line, depending on the latent
indicator variable ηi:
Zi ¼ 0 : yij ¼ s0i þ s1itij þ εij; for j ¼ 1:::Mi
Zi ¼ 1 :
( yij ¼ b0i þ b1itij þ εij; for j ¼ 1:::ki
yij ¼ b00i þ b
0
1itij þ εij; for j ¼ kiþ1:::Mi:
ð1Þ
Here, εij denotes the independent error term, which follows a normal distribution centered
at 0 with variance σ2; ηi denotes the phasic indicator for patient i, with 0 and 1 denoting mono-
and bi-phasic patterns, respectively; ki, a latent variable, denotes the number of observations
belonging to the first phase for patient i, if the response of patient i is bi-phasic. For the indi-
vidual regression parameters, we assume hierarchical normal distributions for si and bi:
si ¼
s0i
s1i
 !

iid N
S0
S1
 
;SS;22
 
¼ NðS;SSÞ ð2Þ
bi ¼
b0i
b1i
b0
0i
b0
1i
0
B
B
B
B
@
1
C
C
C
C
A

iid N
B0
B1
B0
0
B0
1
0
B
B
B
@
1
C
C
C
A
;SB;44
0
B
B
B
@
1
C
C
C
A
¼ NðB;SBÞ ð3Þ
We first consider the artificial case in which we do not know if a patient follows the mono-
or bi-phasic pattern, but if this patient follows a bi-phasic pattern, the associated bi-phasic
design matrix is known. That is, for each patient regardless phasicity, the true mono- and bi-
phasic design matrices are known; the only unknown quantity is the phasicity, ηi. Assuming
the prior distributions P(σ2) = (σ2)−1, P(λ) = Beta(1, 1) = 1, P(SS) = |SS|−(2+1)/2 and P(SB) = |
SB|
−(4+1)/2, where λ denotes the proportion of bi-phasic patients and ηi * Ber(λ), the posterior
Mixture piecewise linear Bayesian hierarchical model
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distribution is:
PðS;SS;B;SB; s2; ljY; ZÞ / ðs2Þ
  1
S  ð2þ1Þ=2S S
  ð4þ1Þ=2
B
YN
i¼1
fð1   lÞPðYijQ
s
iS;Q
s
iSSðQ
s
iÞ
T
þ Is2Þg1  Zi
YN
i¼1
flPðYijQ
b
i B;Q
b
i SBðQ
b
i Þ
T
þ Is2ÞgZi :
ð4Þ
Here η = (η1, . . ., ηN) is the missing indicator variable for phasicity, and Qsi and Q
b
i denote the
individual mono- and bi-phasic design matrices, respectively:
Qsi ¼
1 ti1
..
. ..
.
1 tik
1 tikþ1
..
. ..
.
1 tiMi
2
6
6
6
6
6
6
6
6
6
6
6
6
6
6
4
3
7
7
7
7
7
7
7
7
7
7
7
7
7
7
5
ð5Þ
Qbi ¼
1 ti1 0 0
..
. ..
. ..
. ..
.
1 tik 0 0
0 0 1 tikþ1
..
. ..
. ..
. ..
.
0 0 1 tiMi
2
6
6
6
6
6
6
6
6
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6
6
6
6
6
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3
7
7
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7
7
7
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7
7
7
5
ð6Þ
However, the bi-phasic design matrix for subject i, Qbi , is not known. The estimation of this
bi-phasic change point is a well-known problem in statistics, mathematics, and computer sci-
ence with many applications in other fields; several methods for addressing this question have
been suggested [24, 25]. Here we employed a Bayesian formulation of the change point prob-
lem, suggested by Carlin et al. [26]. For a particular patient i with Mi observations, there are
Mi − 1 possible change points. The cases in which the bi-phasic transition point occurs before
the first observation or after the last observation are ignored, because in such cases mono- and
bi-phasic subjects are not distinguishable. Thus, for each patient i, there are Mi − 1 possible
design matrices, for example:
Qbi1 ¼
1 ti1 0 0
0 0 1 ti2
0 0 1 ti3
..
. ..
. ..
. ..
.
0 0 1 tiMi
2
6
6
6
6
6
6
6
6
6
6
4
3
7
7
7
7
7
7
7
7
7
7
5
ð7Þ
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Qbi2 ¼
1 ti1 0 0
1 ti2 0 0
0 0 1 ti3
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. ..
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0 0 1 tiMi
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ð8Þ
For each corresponding design matrix Qbij, the probability associated with the j-th bi-phasic
design matrix is denoted by πij. Assuming all patients comply with their clinic visit schedules,
such that t11 = t21 = . . . = tN1, . . ., and t1M1 = t2M2 = . . . = tNMN, and assuming an uninformative
Dirichlet prior, Dir(α1 = α2 = . . . = αMi−1 = 1), the posterior function is:
PðS;B;SS;SB; l;p; s2jY; x; ZÞ / ðs2Þ
  1
S  ð2þ1Þ=2S S
  ð4þ1Þ=2
B
YN
i¼1
½ð1   lÞNðYijQ
s
iS;Q
s
i
SSðQsiÞ
T
þ Is2Þ1  Zi ½l
YMi  1
j¼1
fpijNðYijQ
b
ijB;Q
b
ijSBðQ
b
ijÞ
T
þ Is2Þgxij Zi
ð9Þ
where ξij is the unobserved indicator for the jth bi-phasic design matrix for subject i, such that
PMi   1
j¼1
xij ¼ 1 and ξij * Multinomial(πij), and ξi = (ξi0, . . ., ξiMi) and ξ = (ξ1, . . ., ξN); and πij is the
probability that the j-th bi-phasic design matrix is selected for the i-th patient. Note that the
inclusion of the Dirichlet prior results in a constant scaling factor, and hence it is not included
in Eq (9).
Given the complexity of the model, we first used the Expectation Maximization (EM) algo-
rithm to search for the mode of the posterior distribution, which was then used as the starting
value for the Gibbs sampler. To implement the EM algorithm and to obtain Empirical Bayes
estimators, we utilized the procedures derived by Verbeke and Lesaffre [5] and Xu and Hede-
ker [6]. Following the notation used in Xu and Hedeker, the Empirical Bayes estimators for
individual regression parameters and the covariance matrices are given by
s^i ¼ Sþ ðS
  1
S þ ðQ
s
iÞ
T
ðs2IiÞ
  1QsiÞ
  1Qsiðs
2IiÞ
  1
ðYi   QsiSÞ
S^si ¼ ðS
  1
S þ ðQ
s
iÞ
T
ðs2IiÞ
  1QsiÞ
  1
b^ij ¼ Bþ ðS
  1
B þ ðQ
b
ijÞ
T
ðs2IiÞ
  1QbijÞ
  1Qbijðs
2IiÞ
  1
ðYi   QbijBÞ
S^bij ¼ ðS
  1
B þ ðQ
b
ijÞ
T
ðs2IiÞ
  1QbijÞ
  1
:
ð10Þ
for a given set of S, B, SS, and SB.
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In the expectation step, the quantity
zij ¼ Pðxij ¼ 1jB;SB; s2;YiÞ ¼
pijNðYijQbijB;Q
b
ijSBðQ
b
ijÞ
T
þ Is2Þ
XMi   1
j¼1
pijNðYijQ
b
ijB;Q
b
ijSBðQ
b
ijÞ
T
þ Is2Þ
ð11Þ
is calculated. zij denotes the probability of the j-th bi-phasic matrix for the i-th patient is
selected to be bi-phasic design matrix, and zi = (zi1, zi2. . .ziMi). Similarly, the expected value for
ηi can be calculated as
zi ¼ PðZi ¼ 1jS;B;SS;SB; l;s2;YiÞ ¼
lexpðEqð14ÞÞ
ð1   lÞexpðEqð13ÞÞ þ lexpðEqð14ÞÞ
; ð12Þ
where
2logNðYijQsiS;Q
s
iSSðQ
s
iÞ
T
þ Is2Þ ð13Þ
2log
XMi   1
j¼1
pijNðYijQ
b
ijB;Q
b
ijSBðQ
b
ijÞ
T
þ Is2Þ
 !
ð14Þ
and where Eqs (13) and (14) are the posteriors for the mono- and bi-phase pieces. However, in
practice, given the added model complexity of the bi-phasic model compared to the mono-
phasic model, the bi-phasic model has a larger likelihood than the single phasic model, result-
ing in most patients being classified as bi-phasic. To compensate for the difference in model
complexity, we instead of using Eqs (13) and (14) to differentiate each patient’s phasicity, we
used the negative Bayesian Information Criteria (BIC) for the mono- and bi-phasic models,
respectively:
2logNðYijQsiS;Q
s
iSSðQ
s
iÞ
T
þ Is2Þ   2logðMiÞ ð15Þ
2log
XMi   1
j¼1
pijNðYijQ
b
ijB;Q
b
ijSBðQ
b
ijÞ
T
þ Is2Þ
 !
  4logðMiÞ; ð16Þ
The additional terms, −2log(Mi) and −4log(Mi) are constant factors, which can be seen as prior
odds for distinguishing between mono- and bi-phasic models for each patient. Because they
are constants, they only result in a proportional change in the posterior function, Eq (9). Simi-
lar methods of using BIC to determine the posterior model probabilities have been imple-
mented and discussed by Kass and Raftery [27]. BIC corrects for the improvement in fitting
associated with increasing model complexity and BIC has been shown to be a consistent
model selector due to its quickly increasing penalty as a function of the sample size [28–30].
We also investigated AIC as an alternative penalty function. However, as the sample size
increases, the penalty becomes too weak, resulting in mono-phasic patients being misclassified
as bi-phasic patients. In addition, the use of BIC for model selection is analogous to the use of
DIC (Deviance Information Criterion) in Bayesian mixture model [31].
Mixture piecewise linear Bayesian hierarchical model
PLOS ONE | https://doi.org/10.1371/journal.pone.0180756 July 19, 2017 6 / 19
The maximization consists of the following steps:
l^new ¼
1
N
XN
i¼1
zi
S^new ¼
XN
i¼1
ð1   ziÞs^i
XN
i¼1
ð1   ziÞ
S^newS ¼
XN
i¼1
ð1   ziÞðS^si þ ðs^i   S^
newÞðs^i   S^
newÞ
T
Þ
XN
i¼1
ð1   ziÞ þ 2
B^new ¼
XN
i¼1
XMi
j¼0
zizijb^ij
XN
i¼1
zi
S^newB ¼
XN
i¼1
XMi
j¼0
zizijðS^bij þ ðb^ij   B^
newÞðb^ij   B^
newÞ
T
Þ
XN
i¼1
zi þ 2
s^2new ¼
XN
i¼1
ð1   ziÞ½u
s
iðu
s
iÞ
T
þ QsiS^siðQ
s
iÞ
T

XN
i¼1
ð1   ziÞ þ 2
þ
XN
i¼1
XMi
j¼0
zizij½u
b
ijðu
b
ijÞ
T
þ QbijS^bijðQ
b
ijÞ
T

XN
i¼1
zi þ 2
;
ð17Þ
where ubij ¼ Yi   Q
b
ijb^ij.
Updating the probability weight for πij, if all patients adhere to the visit schedule, is straight-
forward by averaging zij. However, in practice, patients often miss scheduled visits entirely or
have unscheduled visits. Such departure from the trial design creates misalignments in
patients’ observation intervals. For instance, two bi-phasic patients, i and i0, are identical except
for their j + 1th visits. Patient i’s j + 1th visit is 1 week later than the scheduled time and patient
i0 is on time. Because of this difference in visit time, zij and zi0j can no longer be simply aver-
aged to update πij. Instead, to account for misalignments, the transition probability πij associ-
ated with bi-phasic transition design matrix Qij needs to adapt to each patient’s actual visit
time. The phasic transition density as a function of time is
yðtÞ ¼
PN
i¼1
PMi  1
j¼1 zijIðtij < t < tiðjþ1ÞÞZi
R T
0
PN
i¼1
PMi   1
j¼1 zijIðtij < t < tiðjþ1ÞÞZidt
: ð18Þ
, where T denotes the maximum follow-up time for all patients. The denominator is the
weighted sum of time interval lengths in which phasic transitions occur; this denominator
serves as the normalizing factor to ensure θ(t) integrates to 1. Eq (14) results in a numeric step-
wise function specifying the transition density at a given t based on the E-step. The weight for
Mixture piecewise linear Bayesian hierarchical model
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each interval for each patient can be updated by integrating over its corresponding interval:
pij ¼
Z tiðjþ1Þ
tij
yðtÞdt: ð19Þ
The starting values for the EM algorithm are obtained using an ad hoc grid search proce-
dure as outlined in S1 File.
The estimated parameter mode from the EM algorithm are used as the starting values for
the Gibbs’ sampler to simulate the posterior distributions of the parameters from the model
specified in Eq (9), as outlined below:
1. Calculate zi for each patient, using Eq (11).
2. For each patient, draw a ξi vector from a multinomial distribution with a parameter vector
zi, and obtain the corresponding bi-phasic design matrix Qbij, such that ξij = 1.
3. Calculate zi based on the mono-phasic design matrix Qsi and the bi-phasic design matrix Q
b
ij
from step (2).
4. Draw ηi from a Bernoulli distribution with parameter zi for each patient.
5. Update θ(t) using Eq (18), with zij replaced by ξij and zi replaced by ηi.
6. Draw a vector πi from a Dirichlet distribution with a parameter vector
ð
R ti2
ti1
yðtÞdt þ 1; :::;
R tiMi   1
tiMi   2
yðtÞdt þ 1Þ, for each patient.
7. Draw λ from a Beta distribution with parameters (
PN
i¼1
Zi þ 1,
PN
i¼1
ð1   ZiÞ þ 1).
8. Sampling si and bi:
si  Nðs^i; S^siÞ
bi  Nðb^ij; S^bijÞÞ
ð20Þ
where s^i and S^si and b^ij and S^bij are from Eq (12). The design matrix for the bi-phasic is
drawn from step (2).
9. Sampling S and B from si and bi:
S  N
XN
i¼1
ð1   ZiÞsi
XN
i¼1
ð1   ZiÞ
;
SS
XN
i¼1
ð1   ZiÞ
0
B
B
B
B
@
1
C
C
C
C
A
B  N
XN
i¼1
Zibi
XN
i¼1
Zi
;
SB
XN
i¼1
Zi
0
B
B
B
B
@
1
C
C
C
C
A
ð21Þ
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10. Sampling SS and SB:
SS  Inv   Wishart
XN
i¼1
ð1   ZiÞ   1;
XN
i¼1
ð1   ZiÞðsi   SÞðsi   SÞ
t
 !
SB  Inv   Wishart
XN
i¼1
ðZiÞ   3;
XN
i¼1
ðZiÞðbi   BÞðbi   BÞ
t
 ! ð22Þ
11. Sampling σ2:
Inv   w2
 
XN
i¼1
Mi;
1
XN
i¼1
Mi
XN
i¼1
fð1   ZiÞðYi   Q
s
isiÞ
t
ðYi   Q
s
isiÞ þ ðZiÞðYi   Q
b
i biÞ
t
ðYi   Q
b
i biÞg
!
ð23Þ
The proposed Gibbs’ sampler is similar to the methods used for variable selection via Gibbs
sampling proposed by George and McCulloch [32], and, Carlin and Chib [33]. The only differ-
ence between our methods and the model by Carlin and Chib is the lack of pseudoprior for the
transition probability between mono- and bi-phasic models. An important consequence of
this is that, as noted in Carlin and Chib’s publication, “it is tempting to skip the generation of
actual pseudoprior values . . . although seemingly reasonable, such an algorithm is clearly not a
Gibbs sampler in the strict sense, since the nodes visited are determined by the current value
in the realized Markov Chain.” However, in practice, as shown by our simulation studies, this
heuristic Gibbs sampler performs well. Other methods such as reversible-jump MCMC may
also be used to sample the posterior distributions [34]; however given the simplicity of the
Gibbs sampler and its close relationship with the EM algorithm, we decided to use Gibbs’ sam-
pler to implement the MCMC chain.
Results
Simulation results
We designed three simulation studies to test the model’s abilities to categorize patients and to
estimate associated parameters, Fig 1. All three scenarios have the same population-level
regression parameters, as shown in Table 1; the differences between the three scenarios lie in
the covariance matrices specifying between-patient variability. The first simulation scenario
assumes that there is no between-patient variability; for the second scenario, there is between-
patient variability in the intercepts and slopes in both mono- and bi-phasic patients but no
correlation among these parameters, i.e. all non-diagonal entries in Ss and Sb are zero. The
third scenario assumes a correlation of 0.5 between the first and second slopes among the bi-
phasic patients. In each scenario, we simulated N = 100 patients. The probability of being a bi-
phasic patient is λ = 0.60. According to a hypothetical clinical protocol, patient data are col-
lected every 21 days with 1 at baseline and 17 at follow-up visits for a total follow-up duration
of 357 days. In this simulation study, the actual visit time may deviate within ± 5 days from the
scheduled time. The true individual regression parameters are drawn from multivariate nor-
mal distributions with respective population parameters and covariance matrices, (S, SS) or
Mixture piecewise linear Bayesian hierarchical model
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(B, SB), depending on patients’ phasicity. For each simulated bi-phasic patient i, the phasic
transition time occurs at t ¼ bi0   b
0
i0
b0i1   bi1
.
We first applied the EM algorithm to estimate the parameter values that maximize the mar-
ginal likelihood. The true and estimated parameters, excluding the covariance for the three
scenarios, are shown in Table 1. In all three scenarios, the proposed model was able to provide
parameter estimates that are close to the true parameter values, except for the bi-phasic pro-
portion parameter λ, which is biased towards the mono-phasic model in scenarios 2 and 3.
Estimating the covariance matrices for scenarios two and three is more challenging, as shown
in Table 2. In particular, we found that the proposed model consistently over-estimates the
variance term associated with the second intercept for the bi-phasic patients. Three possible
causes for this over-estimation are 1) the bi-phasic design matrices must be estimated and mis-
classification of observations between the first and second phases may result in an enlarged
variance term for the second intercept; 2) estimation of the second intercept requires projec-
tion back to time zero, and any uncertainty is magnified by this projection; and 3) the phasic
transition time in our simulated data is distributed according the Gaussian ratio distribution,
Fig 1. Longitudinal trajectories for the simulated patients in the three scenarios. Blue lines indicate mono-phasic patients’ trajectories, and
red lines, bi-phasic patients’ trajectories. Vertical solid lines indicate the median time at which phasic transitions occur for the bi-phasic patients;
vertical dashed lines indicate the 10th% and 90th% phasic transition time. All bi-phasic patients have the same phasic transition time in scenario
one; hence, the dashed and solid lines coincide.
https://doi.org/10.1371/journal.pone.0180756.g001
Table 1. The true and the means of the estimated parameters in the three simulation scenarios.
S0 S1 B0 B1 B00 B01 σ λ
Truth 90 −0.25 91 −0.35 55 −0.15 5.0 0.6
Scenario One 90
(0.33)
−0.25
(0.001)
91
(0.19)
−0.35
(0.002)
57
(1.2)
−0.16
(0.004)
4.9
(0.066)
0.60
(<0.001)
Scenario Two 90
(0.43)
−0.257
(0.005)
90.6
(0.49)
−0.347
(0.006)
56.9
(1.14)
−0.150
(0.005)
5.0
(0.10)
0.50
(0.031)
Scenario Three 89
(0.41)
−0.250
(0.002)
90.8
(0.09)
−0.346
(0.005)
57.5
(0.20)
−0.157
(0.002)
5.1
(0.09)
0.53
(0.007)
The means of the EM estimated parameters over 1000 simulations are shown for each scenario. Standard deviations are shown in parentheses.
https://doi.org/10.1371/journal.pone.0180756.t001
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with heavy tails [35]; thus, bi-phasic patients with extreme transition times may not be classi-
fied correctly. In addition to parameter estimation, the proposed method performed well in
classifying patients according to their phasicities, as shown in Table 3
In addition to the three scenarios outlined above, we also performed sensitivity analyses to
test the effects of variability in population-level intercepts and slopes, S0; S1;B0;B1;B00; and B
0
1
,
on the classification accuracy, Fig 2. For each of the three scenarios, we tested a grid of values
Table 2. The true and the means of estimated covariance components in the three simulation scenarios.
Scenario 1
b0 b1 b00 b01
0 (1.0) 0 (−0.007) 0 (0.242) 0 (−0.001) b0
0 (<0.001) 0 (−0.007) 0 (0.000) b1
s0 0 (0.6) 0 (14.8) 0 (−0.051) b00
s1 0 (−0.003) 0 (<0.001) 0 (<0.001) b01
s0 s1
Scenario 2
b0 b1 b00 b01
4 (6.1) 0 (−0.019) 0 (1.43) 0 (−0.005) b0
0.0009 (0.0006) 0 (−0.011) 0 (<0.001) b1
s0 4 (4.5) 4 (14.8) 0 (−0.051) b00
s1 0 (0.004) 0.0009 (0.0011) 0.0009 (0.0009) b01
s0 s1
Scenario 3
b0 b1 b00 b01
4 (3.4) 0 (−0.006) 0 (0.768) 0 (0.009) b0
0.0009 (0.0005) 0 (−0.014) 0.0005 (0.0005) b1
s0 4 (4.1) 4 (10.1) 0 (−0.036) b00
s1 0 (0.011) 0.009 (0.001) 0.0009 (0.0009) b01
s0 s1
True values are shown outside of the parentheses and estimated values are shown inside the parentheses. The lower triangular components of the mono-
phasic covariance matrix and the upper triangular components of the bi-phasic covariance matrix are shown. The means of the estimated covariance
components are calculated based on 1,000 simulation runs for each scenario.
https://doi.org/10.1371/journal.pone.0180756.t002
Table 3. Classification accuracy for the three scenarios.
Representative examples Scenario 1 Scenario 2 Scenario 3
Estimated Truth Truth Truth
Mono-phasic Bi-phasic Mono-phasic Bi-phasic Mono-phasic Bi-phasic
Mono-phasic 40 0 40 7 40 1
Bi-phasic 0 60 0 53 0 59
Sensitivity/Specificity 100% 100% 100% 88% 100% 98%
Averages of 1,000 simulations 100% 100% 99.99% 82.57% 99.99% 88.40%
A representative example for each scenario and the averages of 1,000 simulation runs are shown. A hard cut-off for calling a patient mono- or bi-phasic is
used based on the expected probabilities of being bi-phasic. Patients with expected bi-phasic probabilities exceeding 0.5 are classified to be bi-phasic,
otherwise mono-phasic.
https://doi.org/10.1371/journal.pone.0180756.t003
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for the bi-phasic first slope, B1 (−0.45, . . ., −0.26), and the second slope, B01 (−0.24, . . ., −0.05),
centering around the mono-phasic slope S1 = −0.25. For this sensitivity analysis, the second
intercept for the bi-phasic patients was kept at values such that the population-level phasic
transition times occurred in the middle of the time span of the trial (178 days). All other
parameters, S0, S1, B0, σ and λ, were kept at the values used in the previous three scenarios. The
covariance matrices, if applicable, were also kept at the values used in the three scenarios. As
expected, as the bi-phasic first and second slopes approached the value of the mono-phasic
slope, the specificity diminished in all three scenarios such that more bi-phasic patients were
misclassified as mono-phasic patients. Due to the strong penalty induced by the BIC correc-
tion in deciding on patients’ phasicities, the proposed model is biased toward the mono-phasic
model. Sensitivity is close to 100% in all three scenarios; hence, the contour plots for sensitivity
are not shown. In addition, we also investigated the effects of the numbers of observations per
patient and the effects of the numbers of patients on the method’s ability to distinguish
between mono- and bi-phasic patterns. As expected, as the number of observations per patient
decreases, specificity decreases. Interestingly, the model is not very sensitive towards the total
number of patients as shown in Fig 3.
We also compared our model and its estimates with a standard mixture model package,
Flexmix, a publicly available package in R [36, 37]. For each simulation, we ran the Flexmix
package with and without providing the true design matrix, and true mixture identity as the
initial values. The true design matrix groups data points from the same phase together for each
subject; the true mixture identity provides the initial clustering of data points from the same
phase across different patients together. The means of the parameters from 1,000 simulations
are shown in Table 4. Because the Flexmix package is not designed to estimate the change
point, the primary comparison of interest is to compare Flexmix’s ability to identify and esti-
mate parameters associated with the three components of the mixture: single-phasic, bi-phasic
first phase, and bi-phasic second phase. For scenario 1, in which is no between-subject
Fig 2. Specificity as a function of true bi-phasic slopes. True mono-phasic slope is kept at −0.25; bi-phasic first slopes vary between −0.45 and −0.26;
bi-phasic second slopes vary between −0.24 and −0.05. Population-level mono-phasic slope and bi-phasic first intercepts are 90 and 91 respectively; the
second slopes for bi-phasic patients are selected such that the population-level phase transition occurs at 178 days, which is in the middle of 357-day trial
period. Each graph is generated based on the averages of 10 simulations. Sensitivity is omitted since it is at 100% for all given scenarios; please refer to
Table 3.
https://doi.org/10.1371/journal.pone.0180756.g002
Mixture piecewise linear Bayesian hierarchical model
PLOS ONE | https://doi.org/10.1371/journal.pone.0180756 July 19, 2017 12 / 19
variability, without providing both true design matrix and mixture identity, the mixture model
was not able to estimate the parameters accurately, as compared to our model Table 1. Provid-
ing the true design matrix and mixture identity greatly improves the mixture model’s ability to
estimate the parameters; however, this improvement is only limited to the case in which there
is no between-subject variability. Once between-subject variability is introduced in scenarios 2
and 3, the mixture model was not able to estimate these parameters correctly.
In addition to obtaining the maximum likelihood parameter estimates, Gibbs’ sampling
was implemented to obtain the posterior densities for the estimated parameters for the three
scenarios. The key parameter of interest in this simulation study is the coverage probability for
the proposed model. We simulated 1,000 independent data sets using identical parameter val-
ues for each scenario. The EM algorithm was first applied to maximize the likelihood; using
the maximum likelihood parameter estimates as starting values, a Markov Chain Monte Carlo
Table 4. Comparison of estimates from a mixture model with and without a true design matrix and true cluster identity using the Flexmix package.
True Parameter Values
Between-Subject Variability True Design Matrix Provided True Cluster Identity Provided S0 S1 B0 B1 B1 B2 σ λ
90 −0.25 91 −0.35 55 −0.15 5.0 0.60
Scenario 1 No No 86 −0.26 86 −0.31 89 −0.25 5.5 0.61
No Yes 85 −0.26 88 −0.33 88 −0.25 5.3 0.59
Yes No 90 −0.25 91 −0.35 57 −0.25 5.1 0.61
Yes Yes 90 −0.25 91 −0.35 55 −0.15 5.0 0.60
Scenario 2 No No 89 −0.26 86 −0.30 90 −0.22 6.2 0.54
No Yes 89 −0.26 86 −0.30 90 −0.22 6.2 0.55
Yes No 87 −0.25 87 −0.31 87 −0.22 6.8 0.58
Yes Yes 89 −0.24 88 −0.30 65 −0.16 6.7 0.64
Scenario 3 No No 88 −0.26 86 −0.30 89 −0.22 6.3 0.54
No Yes 88 −0.26 86 −0.31 90 −0.22 6.3 0.54
Yes No 87 −0.26 87 −0.31 88 −0.21 6.8 0.60
Yes Yes 89 −0.24 88 −0.31 64 −0.16 6.8 0.61
The means of the estimates from 1,000 simulation runs are shown.
https://doi.org/10.1371/journal.pone.0180756.t004
Fig 3. Specificity as a function of the numbers of observations per patient and the total numbers of
patients per simulated data set. Parameter values are identical to those used in the three scenarios. The
numbers of observations per patient vary in the figure on the left; these observations are evenly distributed
between day 0 and day 357. The total numbers of patients, N, vary in the figure on the right; the number of
observations per patient is kept at 18.
https://doi.org/10.1371/journal.pone.0180756.g003
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simulation was performed for each data set, with the number of iterations per simulation equal
to 30,000. With samples generated from the posterior distributions, we constructed a 95%
simultaneous rectangular credible region for each simulated data set, using the method out-
lined by Held [38, 39]. The coverage probability is calculated as the probabilities of the simulta-
neous credible regions covering all 8 parameters for scenario one and covering all 21
parameters for scenarios two and three, out of the 1,000 simulated data sets. The coverage
probabilities are 80.1%, 71.5% and 65.9% for the three scenarios, respectively. The convergence
of the Gibbs’ sampler is shown in S1 File.
We then performed detailed analyses to determine the parameter with the worst coverage
probability in each scenario. For scenario one, the second intercept for the bi-phasic patients,
B0
0
, had the worst coverage probability of only 80.1%. Further analyses of scenarios two and
three revealed that the variance component for the bi-phasic second intercept had the lowest
coverage rate among all parameters; the 95% simultaneous credible regions for all 21 parame-
ters were able to cover the covariance term for the second intercept only at rates of 82.5% and
80.1% for scenarios two and three, respectively. In this case, the covariance components
obtained from the Gibbs’ sampler were consistently higher than the true covariance used in
the simulated data. The same reasons used to explain the enlarged covariance structure for the
EM results can be applied here.
Another parameter of particular interest is the correlation between the first and second
slopes in scenario three. Focusing only on this parameter, our model was able to detect a corre-
lation in 62.1% of the simulation runs; detection refers to 0 being excluded from the 95% credi-
ble region. Overall, the actual coverage probabilities from the proposed model are lower than
the nominal probabilities. Model complexity appears to contribute to this poor coverage, as
previous research has shown that even in the simple binomial case, the coverage probability
rarely agrees with the nominal probability [40]. In addition, the parameter values, particularly
the slopes, used in our simulation have considerable overlaps, which renders identifying
patients’ phasicities difficult, and hence lowers the coverage probabilities.
Application results
To further demonstrate the utility of the proposed methods, we applied it to the M-protein
data from the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Mel-
phalan and Prednisone (VISTA) trial [41]. Briefly, the VISTA trial is a randomized, open-label
phase III study, consisting of 682 patients with newly diagnosed, previously untreated, symp-
tomatic, measurable multiple myeloma. In this study, patients were randomized to treatment
with either melphalan and prednisone with (VMP cohort) or without (MP cohort) bortezomib
(Velcade, Johnson & Johnson Pharmaceutical R&D and Millennium). Measurable disease was
defined as the presence of quantifiable M-protein in serum or urine, or measurable soft-tissue
or organ plasmacytomas. The longitudinal M-protein data from patients in the VISTA trial are
shown in Fig 4.
The parameter estimates from our model revealed several interesting features associated
with the M-protein dynamics, Table 5. First, the differences between the first and second
slopes for the bi-phasic patients in both cohorts are striking. For the bi-phasic patients, the gra-
dient of the first slope was lower than the second slopes in both cohorts, judging by the poste-
rior credible regions. Second, more patients in the VMP cohort displayed bi-phasic
trajectories than in the MP cohort. Third, the gradient of the bi-phasic first slope in the VMP
cohort is lower than that of the bi-phasic first slope in the MP cohort. Fourth, the bi-phasic
first intercepts are similar in both cohorts. Fifth, the long-term declines for the bi-phasic
patients in both cohorts are similar. Sixth, in both cohorts, the intercepts for the mono-phasic
Mixture piecewise linear Bayesian hierarchical model
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patients tend to be substantially smaller than the first intercepts of the bi-phasic patients.
Lastly, in the MP cohort, despite the large differences in the rates of initial declines, the long-
term declines are very similar between the mono-phasic and the bi-phasic patients, as shown
by the similarity in the estimates for S1 and B01. Those observed differences in the M-protein
dynamics between cohorts suggest that the tumor dynamics of multiple myeloma are highly
complex.
Discussion
We have proposed a piecewise linear mixture random-effects model to investigate the extent
of heterogeneity and time-varying functional relationships in longitudinal biomarker data.
The combination of heterogeneity and a time-varying functional relationship is where the
innovation in the proposed model lies. Our model assumes a simple yet robust piecewise linear
functional form. The major advantage of this piecewise linear functional form over other more
complex nonlinear functions is that the likelihood can be maximized analytically, using empir-
ical Bayes estimators and standard expectation-maximization algorithms. No prior knowledge
of the functional relationship other than the piecewise assumption is required; thus this
method is particularly useful for initial exploratory analyses. In addition, the ease of interpreta-
tion of the parameter estimates is another advantage of the proposed model. Lastly, in the
extreme case in which all patients are mono-phasic, the proposed model completely reduces to
linear mixed-effects model.
One minor drawback of our approach is that for the bi-phasic patients, the proposed model
produces a point of discontinuity between ki and ki+1 observations Eq (1). Nonlinear models,
such as the broken-stick model, Bacon Watts model, and the polynomial model suggested by
Matthews et al. offer potential solutions to this problem [42]; however, analytical solutions do
not exist for those nonlinear functions. Another minor problem is that there is a small bias for
the parameter denoting the proportion of bi-phasic patients, λ, in the EM algorithm and
Gibbs’ sampler. Closer investigation reveals that this bias is not due to our proposed model;
rather, it is an artifact of the data generation process for the simulation studies (see S1 File for
Fig 4. Longitudinal trajectories for patients in the VISTA trial separated by treatment cohorts. The
mono-phasic (blue) and bi-phasic (red) lines indicate the population-mean trajectories based on the maximum
likelihood estimates from the EM algorithm.
https://doi.org/10.1371/journal.pone.0180756.g004
Table 5. 95% simultaneous credible regions for the MP and VMP cohorts in the VISTA trial.
Cohorts S0 S1 B0 B1 B00 B01 σ λ
MP (2.34, 3.06) (−0.004, −0.002) (4.35, 5.46) (−0.036, −0.016) (2.23, 3.20) (−0.005, −0.001) (0.25, 0.29) (0.359, 0.592)
VMP (1.06, 2.67) (−0.003, −0.000) (4.00, 4.70) (−0.077, −0.053) (1.12, 1.69) (−0.003, −0.001) (0.22, 0.34) (0.794, 0.938)
https://doi.org/10.1371/journal.pone.0180756.t005
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detail). The simulated data for the bi-phasic patients are generated using a multivariate normal
distribution. An unwanted implication of this generation mechanism is that the phasic transi-
tion time follows a Gaussian Ratio distribution, with heavy tails, such that for some bi-phasic
patients the actual transition time may exceed the window of observation. This problem is par-
ticularly confounding in the case in which the first and second slopes are close in value to the
slope of the true single-phasic slope parameter. As a result, such bi-phasic patients are indistin-
guishable from single-phasic patients. Thus, this small bias indicates that our proposed method
was able to classify these bi-phasic patients “correctly” as single-phasic, based on the observed
data. Fig A in S1 File shows a few such examples. The four figures in the bottom left corner of
Fig A in S1 File are from true bi-phasic patients; however given the late phasic transitions and
steep second slopes, our algorithm is likely to classify them as mono-phasic. This “misclassifi-
cation” is due to the similarity of those patients’ trajectories to those mono-phasic patients
rather than a systematic mistake in our algorithm. Lastly, the MCMC algorithm requires a
large sample size to be implemented due to its model complexity—21 parameters in total. We
recommend a sample size of at least 100 patients and with sufficient numbers of mono- and
bi-phasic patients, greater than 40 each, to ensure that the number of patients is greater than
the number of parameters.
When applying this algorithm to a data set from the VISTA trial, although from our analysis
we have not found a significant correlation between phasicities and patients outcomes, the dis-
tinct mono- and bi-phasic trajectories may have significant medical implications warranting
further investigation and validation. Those findings on the distinct treatment responses for
patients randomized to the same treatment arm may help generate new hypotheses for
improving patient prognosis and disease management.
From the prospective of clinical trial design, one interesting question is how to design a
trial to maximize phasicity detection, if phasicity is important for patient management. Our
linear framework may offer a simple approach to address these issues. In addition, our model
can be extended beyond between-patient variability to include additional layers inside the
hierarchy. For instance, patients with metastatic solid tumors or multiple tumors at different
sites may demonstrate a large degree of similarity in terms of individual tumor trajectories,
yet also exhibit kinetic differences depending on an individual tumor’s microenvironment.
Modeling treatment responses in such scenarios would then require the incorporation of
between-patient variability and within-patient/between-tumor variability into the model. Fur-
thermore, our model can be extended to include multi-category and multi-phasic changes.
The computational tractability problem associated with multi-phasic changes can be addressed
from a practical point of view, such as restricting the number of minimum observations in
each phase to be greater than 5 data points. These additional extensions can further enrich our
proposed model.
Supporting information
S1 File. EM starting value search algorithm, additional EM examples, and assessment of
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